Axial3D

SoftwareBelfast, United KingdomFounded 2015· One of 367 Software companies tracked by AMPulse

AI-powered medical imaging platform that automatically converts 2D medical scans into precise, patient-specific 3D models for surgical planning and diagnostic use.

CEO / Founder: Roger Johnston
Team Size: 51-200
Stage: Active
Total Funding: $36.2M
Latest Round: Series C
Key Investors: 57 Stars ($10M lead), Stratasys ($10M lead), Whiterock, Innovate UK, Techstart Ventures, Clarendon Fund Managers, Imprimatur Capital Fund Management, Innovation Ulster Limited, US surgical angel investors

Technology & Products

Key Products

Axial3D INSIGHT™ (FDA-cleared AI medical image segmentation SaMD, with PCCP) and AXCEL™ (configurable AI platform for medtech: automated DICOM-to-3D segmentation, landmarking, measurements, PSI/device planning, surgical plan approval) enabling patient-specific surgical planning, custom devices, and clinical workflows for hospitals and medical device companies.

Technological Advantage

FDA-cleared, patented AI/ML medical image segmentation (Axial3D INSIGHT™) with Predetermined Change Control Plan (PCCP) enabling continuous algorithm updates without repeated FDA submissions; cloud-native AWS platform for scale; strategic partnership with Stratasys for anatomic model printing and distribution.

Differentiation

Value Proposition

To make patient-specific surgical planning routine and accessible by providing automated, fast, and accurate 3D anatomical models, leading to improved surgical outcomes and reduced costs.

How They Differentiate

Axial3D differentiates itself through its focus on a highly automated, AI-powered software platform that integrates seamlessly into clinical workflows. This software-first approach, combined with its strategic partnership with Stratasys for printing, allows for greater scalability and accessibility compared to competitors who may have a more service-oriented or machine-focused business model.

Market & Competition

Target Customers

Hospitals, surgeons, and medical device manufacturers.

Industry Verticals

Healthcare

Competitors

Materialise; 3D Systems; Ricoh 3D for Healthcare

Growth & Milestones

Growth Metrics

While specific revenue figures are not public, the company's significant and successful funding rounds, strategic partnerships, and FDA clearance indicate strong growth and market traction.

Major Milestones

Received FDA 510(k) clearance for Axial3D INSIGHT™ medical image segmentation platform., Secured $15M funding round led by $10M strategic investment from Stratasys (Nov 2022)., Raised $18.2M (Dec 2024) led by 57 Stars to scale AI tech and US presence., Oct 2025: FDA granted Predetermined Change Control Plan (PCCP) clearance for Axial3D INSIGHT™ — first image-segmentation company with PCCP plus foundational AI/ML segmentation patents.

Notable Customers

Belfast City Hospital (kidney transplant backlog during COVID-19); University Hospital Southampton (complex heart surgery 3D models featured by BBC News)

https://axial3d.com

Why this company matters

AMPulse analysis, not a company disclosure

Axial3D occupies a specific niche in medical 3D printing: automating the labor-intensive step of converting DICOM data from CT, MRI, and PET scans into segmented 3D anatomical models. While hospitals and service bureaus have long produced patient-specific models manually, Axial3D's software-first approach uses FDA-cleared AI to reduce turnaround time and cost, aiming to make such models routine rather than exceptional for surgical planning and device development.

The core product is an AI-powered platform that ingests standard medical imaging formats and outputs ready-to-print or viewable 3D models. The company does not manufacture its own printers; instead, it relies on a strategic partnership with Stratasys for access to polymer AM technology and a global distribution channel. This software-plus-partner model allows Axial3D to scale without the capital intensity of operating a print farm.

Primary customers are hospitals and surgeons, with medical device manufacturers as a secondary segment. A notable deployment occurred at Belfast City Hospital, where Axial3D's models helped clear a kidney transplant backlog during the COVID-19 pandemic by enabling faster, more precise pre-surgical planning. The company has raised $36.2 million from investors including Stratasys and 57 Stars, and received FDA 510(k) clearance for its Axial3D INSIGHT segmentation platform.

Axial3D's main competitive risk is that larger players like Materialise and 3D Systems offer broader medical software suites and printing services. Axial3D differentiates by focusing purely on AI-driven automation and workflow integration, rather than selling hardware or acting as a full-service bureau. The open question is whether its software-first model can achieve the hospital adoption and reimbursement support needed to make patient-specific modeling a standard of care, or whether it remains a niche tool for complex cases.